- Home
- CMMB vs BLRX Comparison
CMMB vs BLRX Comparison
Compare CMMB & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | BLRX |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.6M |
| IPO Year | 2023 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CMMB | BLRX |
|---|---|---|
| Price | $2.25 | $3.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $25.00 | $19.00 |
| AVG Volume (30 Days) | ★ 104.3K | 14.7K |
| Earning Date | 05-21-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $2.15 |
| 52 Week High | $3.86 | $5.05 |
Technical Indicators
Market Signals| Indicator | CMMB | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 74.41 | 54.03 |
| Support Level | $1.48 | $3.05 |
| Resistance Level | $2.80 | $3.51 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 84.04 | 49.57 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.